Information Provided By: 
Fly News Breaks for October 15, 2019
RARX
Oct 15, 2019 | 05:23 EDT
Credit Suisse analyst Martin Auster downgraded RA Pharmaceuticals to Neutral from Outperform with a $48 price target. The downgrade comes after UCB and Ra Pharmaceuticals announced their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive $48 in cash for each Ra Pharma share at closing.
News For RARX From the Last 2 Days
There are no results for your query RARX
